JP6734101B2 - Heart rate recovery promoting composition - Google Patents

Description

The present invention is a composition for promoting the recovery of heart rate containing astaxanthin as an active ingredient, by administering to humans or animals as a drug or ingesting as a food, the heart rate increased by exercise or stress is promptly at rest. The present invention relates to drugs and foods that are effective in promoting the recovery of heart rate by returning to

The heart rate of the heart increases with exercise. In competitive animals such as athletes and racehorses, the increased heart rate can be quickly restored to normal, resulting in smoother response to the next round and improved exercise performance.

Astaxanthin is known as a composition that is naturally derived or synthetic, has no side effects, and can be easily ingested as a food.

In addition, astaxanthin is a type of carotenoid similar to β-carotene, shrimp, crabs and other crustaceans, salmon, fish such as Thailand, algae such as green alga Hematococcus, yeasts such as red yeast phaffia, natural, especially in the ocean. It is a red pigment that is widely distributed and has a good dietary experience, and it has been found to have a strong antioxidant effect that is about 1,000 times that of vitamin E and about 40 times that of β-carotene.

Other functional properties of astaxanthin include anti-inflammatory action, anti-atherosclerotic action, diabetic action, retinal protection action from photodamage, diurnal rhythm control action, immunostimulatory action, anti-stress action, sperm quality improving action. And suppression of bladder cancer induction have been reported. Further, as effects of astaxanthin on exercise, improvement of muscle endurance, reduction of muscle fatigue, prevention of sarcopenia, improvement of heart failure, improvement of performance in aerobic exercise/anaerobic exercise/intermittent anoxic exercise, etc. have been reported.

For example, astaxanthin functions include exertional rhabdomyolysis of horses (Patent Document 1), recovery of fatigue after exercise (Patent Document 2, Non-Patent Document 1), reduction of oxidative stress after exercise (Patent Document 3), It has been reported to be effective for improving energy production and metabolism (Patent Document 4), and there is also a report on the effect of astaxanthin on physiological functions during exercise load (Non-Patent Document 2).

Japanese Patent Publication No. 2001-514215 JP, 2006-016409, A Japanese Patent Publication No. 2007-532121 JP, 2009-215170, A

The Science of Fatigue and Rest, 18(1), 35-46, 2003 Health and Behavior Sciences 3(1), 5-10, 2004

However, astaxanthin has a functional property of promoting recovery of heart rate, that is, an effect of rapidly returning a heart rate increased by exercise to a normal value has not been reported yet.

Accordingly, the present invention provides a composition for rapidly returning the heart rate increased by exercise or the like to a normal value in humans or animals, and as a result, improving exercise performance, and a pharmaceutical product or a food or drink comprising the composition. This is an issue.

As a result of intensive studies to solve the above problems, the present inventors have found that astaxanthin exhibits a heart rate recovery promoting effect, and have completed the present invention.

That is, the composition according to claim 1 of the present invention is a composition for promoting heart rate recovery, which comprises astaxanthin as an active ingredient.

The composition according to claim 2 of the present invention is the composition for promoting the recovery of heart rate according to claim 1, wherein the recovery of the heart rate is recovery of the heart rate after the increase of the heart rate by exercise. It is what

Moreover, the composition according to claim 3 of the present invention is characterized in that, in the composition for promoting the recovery of heart rate according to claim 1 or 2, astaxanthin is derived from Haematococcus alga. is there.

The composition according to claim 4 of the present invention is the composition for promoting heart rate recovery according to any one of claims 1 to 3, wherein astaxanthin is a fatty acid ester. It is a thing.

The composition according to claim 5 of the present invention is the composition according to any one of claims 1 to 4, which is a pharmaceutical composition for heart rate recovery treatment.

The composition according to claim 6 of the present invention is the composition according to any one of claims 1 to 4, which is a food and drink composition for heart rate recovery.

In the present invention, “astaxanthin” means a substance derived from a natural product or a substance obtained by chemical synthesis. As those derived from natural products, for example, shrimp, krill, crustaceans of crustaceans such as crab, eggs and organs, skins and eggs of various seafood, algae such as green alga Hematococcus, yeasts such as red yeast fafia, Mention may be made of those obtained from seed plants such as marine bacteria, Fukujukusa and Kinhobana. Since astaxanthin derived from a natural product and a chemically synthesized product of astaxanthin are commercially available or manufactured by a known method, they are easily available.

The astaxanthin derived from a natural product can be obtained by culturing, for example, red yeast Phaffia, green alga Hematococcus, marine bacteria, etc. in an appropriate medium according to a known method. The green alga Haematococcus is most preferred as a natural product because it is easy to culture and extract, contains astaxanthin at the highest concentration, and has high productivity. As a culture method for obtaining a green alga Haematococcus having a high astaxanthin content, a closed culture method in which there is no contamination/proliferation of heterologous microorganisms and other contaminants are small, for example, a closed dome shape, a cone A method of culturing using a culture medium having a shaped or cylindrical culture device and a gas discharge device movable in the device (WO 99/050384), or putting a light source in a closed culture device to emit light from the inside. A method of irradiating and culturing and a method of culturing in a plate-shaped culture tank are suitable.

Various methods are known for extracting and purifying astaxanthin. For example, since astaxanthin and its ester are oil-soluble substances, astaxanthin can be extracted from the above natural products with an oil-soluble organic solvent such as acetone, alcohol, ethyl acetate, benzene and chloroform. Supercritical extraction can also be performed using carbon dioxide or water. After extraction, the solvent is removed by a conventional method to obtain a mixed concentrate of monoester-type astaxanthin and diester-type astaxanthin. Furthermore, this concentrate can be purified by a separation column or lipase decomposition.

The Haematococcus algae cultivated in the above dome-shaped culture device is dried, and then crushed and then extracted with acetone, or after crushing and extracting in acetone at the same time, the method of removing acetone and extracting astaxanthin is a contaminant. It is preferable that the amount is small, that is, the substance that inhibits the effect of promoting the recovery of heart rate of the present invention is small, and astaxanthin and triglyceride can be contained in high purity.

As the use form of astaxanthin, astaxanthin extract obtained by the above method, powder or aqueous solution containing astaxanthin extract, or red yeast Phaffia, green alga Hematococcus, it is possible to use dried products or crushed products such as marine bacteria. it can.

A chemically synthesized product of astaxanthin can be obtained by a known method. For example, a method for synthesizing astaxanthin in the form of dimethyl ester (Surmatis, JD et al.: J. Org. Chem., 32, 180-184, 1967), a method for synthesizing astaxanthin free form from canthaxanthin (Leftwick, AP et al.: J. Chem. Soc., Chem. Comm., 49-50, 1967) are known. In addition, a method for synthesizing astaxanthin in which a phosphonium salt of a C ₁₅ -endo group is bound to both ends of a C ₁₀ -dialdehyde by the Hoffmann-Laroche group by a Wittig reaction (Britton, G. et al.: Carotenoids vol.2 Synthesis, Birkhauser Verlag, Basel) , 1996) is used as an industrial synthetic method. Further, a method for producing a water-soluble astaxanthin derivative is also known (International Publication No. 2004/011423, International Publication No. 2003/066583).

The free form of astaxanthin is 3,3′-dihydroxy-β,β-carotene-4,4′-dione, which has stereoisomers. Specifically, three stereoisomers of (3R,3′R)-astaxanthin, (3R,3′S)-astaxanthin and (3S,3′S)-astaxanthin are known, but the present invention Any of them can be used for

Astaxanthin is known to be a highly safe compound with no observed mutagenicity, and is widely used as a food additive (Jiro Takahashi et al.: Toxicity test of hematococcus alga Astaxanthin-Ames test, Rat single dose toxicity test, rat 90-day repeated oral dose toxicity test-clinical medicine, 20:867-881, 2004.).

Unless stated otherwise in the description of the present invention, astaxanthin includes a free form of astaxanthin and/or its ester. Furthermore, the ester of astaxanthin includes a monoester body and/or a diester body. It is known that astaxanthin derived from Haematococcus alga mainly contains a monoester.

At least one of an astaxanthin free form, a monoester form, and a diester form can be used in the composition for promoting recovery of heart rate of the present invention. Since the diester form has two hydroxyl groups protected by ester bonds, it is chemically and physically more stable than the free form and monoester form and is less susceptible to oxidative decomposition in the composition of the present invention. However, it is considered that when it is taken into the living body, it is rapidly hydrolyzed to astaxanthin by an enzyme in the living body and exhibits an effect.

Examples of astaxanthin monoesters include lower saturated fatty acids, higher saturated fatty acids, lower unsaturated fatty acids, and monoesters esterified with higher unsaturated fatty acids. Specific examples of the lower saturated fatty acid, higher saturated fatty acid, lower unsaturated fatty acid, higher unsaturated fatty acid, acetic acid, citric acid, lauric acid, myristic acid, pentadecanoic acid, palmitic acid, palmitooleic acid, heptadecanoic acid, Elaidic acid, ricinoleic acid, betroceric acid, vaccenic acid, eleostearic acid, punicinic acid, licanoic acid, parinaric acid, gadolic acid, 5-eicosenoic acid, 5-docosenoic acid, cetolic acid, erucic acid, 5,13-docosadiene Examples thereof include acids, ceracolic acid, decenoic acid, steric acid, dodecenoic acid, oleic acid, stearic acid, eicosaopentaenoic acid, docosahexaenoic acid, linoleic acid, linolenic acid and arachidonic acid. Also, amino acids such as glycine and alanine; inorganic acids such as phosphoric acid and sulfuric acid; sugars such as glucoside; sugar fatty acids such as glycerosugar fatty acid and sphingosugar fatty acid; fatty acids such as glycerofatty acid; monoesters esterified with glycerophosphoric acid and the like. Esters can be mentioned. The salts of the above monoesters are also included. Among the above, preferred are palmitic acid, oleic acid, linoleic acid and linolenic acid, more preferred are palmitic acid and oleic acid, and more preferred are monoesters esterified with oleic acid.

The astaxanthin diester is the same selected from the group consisting of the above lower saturated fatty acid, higher saturated fatty acid, lower unsaturated fatty acid, higher unsaturated fatty acid, amino acid, inorganic acid, sugar, sugar fatty acid, fatty acid and glycerophosphoric acid. Alternatively, diesters esterified with different acids can be mentioned. The salts of the above diesters are also included. Examples of the diester of glycerophosphoric acid include saturated fatty acid esters of glycerophosphoric acid, glycerophosphoric acid esters containing fatty acids selected from higher unsaturated fatty acids, unsaturated fatty acids or saturated fatty acids, and the like. Of the above, preferably diesters esterified with the same or different acid selected from palmitic acid, oleic acid, linoleic acid, linolenic acid, more preferably palmitic acid, oleic acid, more preferably oleic acid. You can

Examples of the salts of astaxanthin monoesters and diesters include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; aluminum salts, iron salts, and the like. Metal salts; amine salts such as ammonium salts and t-octylamine salts; amino acid salts such as lysine salts and ornithine salts; hydrohalides such as hydrofluorides and hydrochlorides; nitrates; perchloric acid Salt; Sulfate; Phosphate; Sulfonate such as methanesulfonate, trifluoromethanesulfonate; Carboxylate such as acetate, malate; or Amino acid such as glutamate, aspartate It is salt.

In order to enhance the effect of astaxanthin of the present invention for promoting the recovery of heart rate, an active oxygen scavenger can be added as a water-soluble additive and/or a water-insoluble additive. Examples of the active oxygen scavenger include vitamin E such as vitamin E acetate and derivatives thereof and salts thereof; tocotrienols and derivatives thereof and salts thereof; ascorbic acid, phosphoric acid-L-ascorbyl magnesium, L-ascorbic acid sulfate. Vitamin C and derivatives thereof such as disodium and vitamin C dipalmitate and salts thereof, vitamin D and derivatives thereof and salts thereof; vitamin A acetate and vitamin A such as vitamin A palmitate and derivatives thereof and salts thereof Vitamin Bs and their derivatives and salts thereof; plant extracts containing flavonoids such as ginkgo biloba extract, gokahi extract, yashajitsu extract, zikoppi extract in its components; serum deproteinization extract, spleen extract, Extracts derived from animals such as placenta extract, corolla extract and royal jelly; plant-derived extracts such as carrot extract, assembly extract, rosemary extract, oat extract, garlic extract, hinokitiol and cepharanthin; yeast Extracts derived from microorganisms such as extract, lactic acid bacterium extract, bifidobacteria extract, and Reishi extract; vitamins such as butylhydroxytoluene (BHT) and butylhydroxyanisole (BHA); deoxyribonucleic acid and its salt, adenosine Adenylic acid derivatives such as phosphoric acid and adenosine monophosphate, and salts thereof, ribonucleic acid and salts thereof, guanine, xanthine and derivatives thereof, and salts thereof, and other nucleic acid-related substances; glutathione and derivatives thereof and salts thereof; α -Or γ-linoleic acid, eicosapentaenoic acid and derivatives thereof; succinic acid and derivatives thereof and salts thereof: estradiol and derivatives thereof and salts thereof; α-such as lactic acid, glycolic acid, citric acid, malic acid and salicylic acid Hydroxy acids and their derivatives and salts thereof; hydroquinone, bilirubin, cholesterol, tryptophan, histidine, quercetin, quercitrin, gallic acid, gallic acid derivatives and the like. Of the above, preferably vitamin E and its derivatives and salts thereof, tocotrienol and its derivatives and salts thereof, vitamin C and its derivatives and salts thereof, and more preferably tocotrienol is mentioned.

The tocotrienol is reported to have a cholesterol lowering action, an arteriosclerosis improving action, a breast cancer cell growth inhibiting action, etc., in addition to the action of removing active oxygen, and also an angiogenesis inhibiting action, a whole blood fluidity improving action, New functionalities such as erythrocyte membrane deformability improving action have also been discovered. In Europe and the United States, it is widely used as a next-generation vitamin E for external use such as cosmetics. Tocotrienols can be obtained by methods such as squeezing natural products, extracting from natural products, and synthesizing. Generally, it is extracted from the peel and/or seed of a palm plant. Tocotrienols obtained from extracts of natural products are a mixture of multiple tocotrienol isomers. These have been applied to food additives, cosmetics, etc. by utilizing their antioxidant effect.

The tocotrienol means α-tocotrienol, β-tocotrienol, γ-tocotrienol, δ-tocotrienol, and esters of each of these isomers such as nicotinic acid, acetic acid and succinic acid. These tocotrienols include d-, 1-, and dl-type isomers. Further, they can be used as a mixture of one or more or two or more of them.

These tocotrienols can be obtained by a conventional method, for example, a method such as pressing a natural product, extracting from a natural product, or synthesizing. If desired, these tocotrienols may be further purified by further separation and purification, for example, by column chromatography.

In the composition of the present invention, the active oxygen scavenger is contained in an amount of 0.1 to 10 parts by weight, preferably 0.2 to 5 parts by weight, based on 1 part by weight of astaxanthin.

The composition of the present invention is prepared by a conventional method, for example, tablets, sublingual tablets, pills, suppositories, powders, powders, fine granules, granules, capsules, microcapsules, injections, emulsions, patches. And the like. For example, tablets can be produced by uniformly mixing with a pharmacologically acceptable carrier to form tablets, and powders, powders and granules can be produced by dry granulation or wet granulation of the drug and carrier. The wet granulation can be carried out by a conventional method, for example, a spray drying method, a fluidized bed granulation method, a kneading granulation method or a freeze drying method. If necessary, chewable tablets and orally rapidly disintegrating tablets can be prepared by a conventional method.

Powders, powders, fine granules, granules, tablets are lactose, glucose, sucrose, mannitol, magnesium aluminometasilicate, hydrotalcite, anhydrous calcium phosphate, sorbitol, mannitol, xylitol, erythritol, maltitol, lactose. , Excipients such as sucrose, magnesium aluminometasilicate, magaltolate, anhydrous calcium phosphate, calcium carbonate, starch, sodium alginate, agar, crosbovidone, disintegrating agents such as crystalline cellulose, magnesium stearate, talc, silicon dioxide, polyethylene glycol And the like, binders such as polyvinyl alcohol, hydroxypropyl cellulose, methyl cellulose, gelatin and starch, surfactants such as fatty acid esters, plasticizers such as glycerin, flavoring agents, sweeteners and the like.

If necessary, an antioxidant may be further added to the composition of the present invention. The antioxidant is not particularly limited as long as it has an antioxidant effect. For example, the aforementioned active oxygen scavenger, coenzyme Q, flavonoid, tannin, ellagic acid, polyphenols, radical inhibitors, hydroperoxide decomposing agents, metal chelating agents, α-carotene, β-carotene, γ-carotene, and δ- One or two or more kinds can be selected from the group consisting of carotenes including carotene, tocoquinone, pharmaceutically acceptable salts thereof, and a mixture thereof.

Injectables can be prepared by a conventional method in the presence of an active ingredient, if necessary, a pH adjusting agent, a buffering agent, a dissolving agent, a suspending agent, a tonicity agent, a stabilizer, a preservative and the like. ..

Examples of the suspending agent include polysorbate 80, methyl cellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyoxyethylene sorbitan monolaurate, gum arabic, and powdered tragacanth. Examples of the solubilizer include polysorbate 80, hydrogenated polyoxyethylene castor oil, nicotinic acid amide, polyoxyethylene sorbitan monolaurate, macrogol, and castor oil fatty acid ethyl ester. Examples of the stabilizer include sodium sulfite and sodium metasulfite. Examples of the preservatives include methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, sorbic acid, phenol, cresol, chlorocresol and the like.

The amount of astaxanthin in the medicine of the present invention can be contained in an amount of 0.01 to 99% by weight, preferably 0.1 to 90% by weight.

The dose of astaxanthin or its ester to be mixed in the medicine of the present invention per day for an adult is 0.01 to 2 mg/kg body weight, preferably 0.04 to 0.24 mg/kg body weight in terms of astaxanthin free form. And is administered orally or parenterally. The dose depends on the age, body weight, degree of symptoms, and administration form of the patient to be administered.

As an administration method, the above-mentioned daily dose can be administered once to several times a day from 2 to 3 weeks before the exercise load is given. Also, the above-mentioned daily amount can be administered 1 to 2 hours before the exercise load is applied.

The composition for promoting recovery of heart rate of the present invention can be used by blending it with food and drink.

As food and drink, it can be used as a supplement, health food, food with health claims such as food with nutritional function or food for specified health use, special purpose food, general food, quasi-drug or supplement for sports. Supplements, supplements for sports, diets with health claims, and special-purpose foods are preferable because the ease and the amount of intake can be easily determined.

When the food of the present invention is used as a dietary supplement or a functional food, its form may be the same as the above-mentioned pharmaceutical preparation. A mixture of milk protein, soybean protein, egg albumin protein, or the like, or a degradation product of egg white oligopeptide, soybean hydrolyzate, and amino acid alone can be used in combination. In addition, natural liquid foods containing sugars, fats, trace elements, vitamins, emulsifiers, flavors, etc., processed foods such as semi-digestive nutrition foods and nutritional foods, drinks, capsules, enteral nutrition it can. When provided in the form of a drink, nutritional additives such as amino acids, vitamins and minerals, sweeteners, spices, flavors and pigments may be added to improve nutritional balance and flavor when ingested. The form of the food of the present invention is not limited to these.

General foods, that is, examples of forms of food and drink, margarine, butter, cheese, fresh cream, yogurt, dairy products, meat products, fish products, french fries, chewing gum, chocolate, jelly, candy, castella, cakes, pasta, Examples include salad oil, instant soup, dressing, eggs, mayonnaise, carbonated or non-carbonated beverages such as soft drinks, sports beverages, non-alcoholic or liqueurs such as tea and coffee, alcoholic beverages such as medicinal liquor, etc. it can.

The food of the present invention is produced by blending astaxanthin or its ester together with the raw materials of general foods, and processing and producing it according to a conventional method. The compounding amount of astaxanthin or its ester varies depending on the form of food and is not particularly limited, but is generally 0.00001 to 10% by weight, preferably 0.0001 to 5% by weight, and has a heart rate recovery promoting action. It is prepared so as to contain only the amount necessary for producing. The amount of astaxanthin or its ester used can be appropriately selected by those skilled in the art according to the type of food and drink, and is 0.2 to 100 mg, preferably 0.5 to 20 mg per adult daily intake.

Even when the composition for promoting heart rate recovery of the present invention is added to a feed, it is possible to obtain the same effects as pharmaceuticals and foods and drinks, for example, mouse, rat, rabbit, monkey, dog, cat, pig, cow, It can be given to sheep, horses and birds.

The daily intake of astaxanthin or its ester incorporated in the food or feed of the present invention in human or animal is 0.01 to 2 mg/kg body weight, preferably 0.04 to 0. It is 24 mg/kg body weight, and varies depending on the form of food and feed.

With the heart rate recovery promoting effect in the present invention, by administering the composition for promoting heart rate recovery of the present invention, the heart rate after a certain period of time after exercise load is significantly lower than the heart rate in the control group. This is the effect of rapidly reducing the increase in heart rate that occurs after exercise to the resting heart rate. And, in particular, it is to promote recovery against an increase in heart rate due to exercise with high load intensity.

The composition for promoting the recovery of heart rate in the present invention contains non-toxic astaxanthin as an active ingredient, and by continuously administering the composition as a medicine or a food, without an adverse effect, an increase in heart rate caused by exercise load can be achieved. It has the effect of quickly reducing the resting heart rate.

8 is a bar graph showing the average heart rate in a control group and an astaxanthin administration group 8 minutes after the final sprint in Test Example 1. 9 is a bar graph showing the average time in each group until the heart rate returns to 30% when the resting heart rate returns to 100% immediately after the final sprint in Test Example 1.

The following examples are provided to explain the present invention in more detail, but it goes without saying that the present invention is not limited to these examples.

[Test Example 1]
The astaxanthin used in the test is a Haematococcus alga containing Astaxanthin at 5% (manufactured by Astaryl Co., Ltd.). A test sample was prepared by suspending 100 mg of this Haematococcus alga in 1 mL of olive oil and adjusting the amount of astaxanthin to 5 mg (hereinafter referred to as “suspension containing 5 mg of astaxanthin”). Further, 1 mL of olive oil was used as a test sample for the control group to which astaxanthin was not given.

Twelve male Wistar rats (body weight: 200 to 250 g) were bred under the conditions of a temperature of 21 to 25° C., a light of 12 hours, and a dark of 12 hours during the test period. They were given water and food ad libitum for 2 weeks to get used to the environment. After that, they were divided into the following two groups each consisting of 6 animals.
(1) Control group: Olive oil 1 mL once a day by gavage (2) Astaxanthin administration group: Astaxanthin 5 mg suspension once a day by gavage

After acclimatization to each group for 3 weeks without performing the above-mentioned forced oral administration, 5 rats in good condition were selected from each group, and a heart rate measuring monitor device (manufactured by Star-Oddi) was prepared in all rats. Embedded. Thereafter, each test sample was forcibly orally administered to each group once a day, and in parallel, a test for giving an exercise load was performed.

That is, a series of exercises in the order of (A), (B), (C), and (D) was applied twice a week for 4 weeks on a treadmill [running machine for rats: manufactured by Columbus Instruments]. .. The tilt of the treadmill was 5 degrees.
(A) Run for 30 minutes at a speed of 30 m/min (B) Run for 7 minutes Break (C) Run for 15 minutes at a speed of 30 m/minute (D) Run for 1 minute at a speed of 40 m/minute (hereinafter referred to as "final sprint") .)
This exercise load was performed 1-2 hours after the oral gavage of each test sample to each group. Then, after the exercise load, the rat body weight, food intake, and health findings were measured and observed.

After the end of the exercise test for 4 weeks, the heart rate measuring monitor was taken out from the rat body, and the fluctuation of the heart rate was examined.

During the test period, no health problems due to test sample administration or exercise load were observed in any of the rats. In addition, there was no difference in body weight or food intake between the groups.

The average heart rate and standard deviation 8 minutes after the end of the final sprint of each group on the 28th day, which is the final day of the 4-week exercise stress test, are shown in Table 1 and FIG.

[Table 1]
Average heart rate after the final sprint

The average heart rate of the astaxanthin administration group was significantly lower than that of the control group (p<0.01), and astaxanthin administration promoted recovery after the increase of heart rate due to exercise load.

On the 28th day, which is the last day of the 4-week exercise stress test, the average in each group until returning to 30% when the rate from the heart rate immediately after the final sprint of each group to returning to resting heart rate is 100% The time and standard deviation are shown in Table 2 and FIG.

[Table 2]
Average time to return your heart rate to 30%

The average time of the astaxanthin-administered group until it returned to 30% was significantly shorter than the average time of the control group, when the rate from the heart rate immediately after the final sprint to the resting heart rate was set to 100% ( (p<0.01), administration of astaxanthin promoted recovery after heart rate increase due to exercise load.

[Formulation Example 1] Tablets The following ingredients were uniformly mixed in the following composition ratio (% by weight) to give tablets each having 300 mg.
Hematococcus algae extract 30 mg
Lactose 70mg
70 mg starch
Casein sodium 6mg
Gelatin 6mg
Cellulose 109 mg
Silicon dioxide 3 mg
Sucrose fatty acid ester 6mg
The Haematococcus alga extract contains 5% by weight of astaxanthin in terms of free form.

[Formulation Example 2] Soft capsule agent A soft capsule capsule consisting of the following components was filled with a Haematococcus alga extract (containing 5% by weight of astaxanthin in terms of free form) by a conventional method to obtain 300 mg soft capsules per capsule. ..
Contents Haematococcus algae extract 20 mg
Edible oil and fat 150mg
Skin gelatin 100 mg
Glycerin 30mg

[Formulation Example 3] Drink preparation A drink preparation was prepared by adding the following components and adding 10 kg of water according to a conventional method.
Hematococcus algae extract aqueous solution * 25g
Liquid sugar 4000g
DL-sodium tartrate 1g
Citric acid 50g
Vitamin C 50g
Vitamin E 150g
Cyclodextrin 25g
Potassium chloride 5g
2g magnesium sulfate
*Hematococcus alga extract aqueous solution (containing astaxanthin 1%) prepared by the method of Example of JP 2001-316601 A

Claims (5)

A composition for promoting heart rate recovery comprising astaxanthin as an active ingredient ,
A composition for promoting recovery of heart rate, wherein the promotion of recovery of heart rate is promotion of recovery to resting heart rate after increase in heart rate by exercise . The composition for promoting heart rate recovery according to claim 1, wherein the astaxanthin is derived from Haematococcus alga. The composition for promoting heart rate recovery according to claim 1 or 2, wherein astaxanthin is a fatty acid ester. The composition according to any one of claims 1 to 3, which is a pharmaceutical composition for treatment for promoting recovery of heart rate. The composition according to any one of claims 1 to 3, which is a food and drink composition for promoting recovery of heart rate.

Images